Recruiting
BRAF V600E mutation positive+1
RecruitingRegistered drugNo placebo
Study on the Effectiveness and Safety of Plixorafenib (FORE8394) for Patients with Cancer Having BRAF Alterations
Registered drugNo placebo
- Disease:BRAF V600E mutation positiveBRAF gene mutation
- Substances:Cobicistat(3R)-N-[3-[5-(2-Cyclopropylpyrimidin-5-Yl)-1H-Pyrrolo[2,3-B]Pyridine-3-Carbonyl]-2,4-Difluorophenyl]-3-Fluoropyrrolidine-1-Sulfonamide
Countries:
France
France- Participants:0–17 years · 18–64 years · 65+ years
- Substances:Cobicistat












